Your browser is no longer supported. Please, upgrade your browser.
INmune Bio, Inc.
Index- P/E- EPS (ttm)-0.97 Insider Own45.07% Shs Outstand12.93M Perf Week-5.93%
Market Cap228.59M Forward P/E- EPS next Y-1.39 Insider Trans0.00% Shs Float7.39M Perf Month-9.73%
Income-11.20M PEG- EPS next Q-0.31 Inst Own11.60% Short Float6.06% Perf Quarter100.35%
Sales- P/S- EPS this Y41.50% Inst Trans-7.57% Short Ratio1.33 Perf Half Y76.96%
Book/sh3.19 P/B5.32 EPS next Y-27.50% ROA-39.30% Target Price26.00 Perf Year280.49%
Cash/sh1.80 P/C9.41 EPS next 5Y- ROE-41.20% 52W Range2.20 - 29.99 Perf YTD-1.45%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-43.41% Beta-
Dividend %- Quick Ratio17.70 Sales past 5Y- Gross Margin- 52W Low671.36% ATR1.98
Employees4 Current Ratio17.70 Sales Q/Q- Oper. Margin- RSI (14)41.79 Volatility9.47% 8.90%
OptionableNo Debt/Eq0.00 EPS Q/Q-28.00% Profit Margin- Rel Volume0.64 Prev Close16.22
ShortableYes LT Debt/Eq0.00 EarningsMar 04 AMC Payout- Avg Volume336.34K Price16.97
Recom1.70 SMA20-12.09% SMA50-7.01% SMA20053.43% Volume208,340 Change4.62%
Jan-22-21Reiterated Maxim Group Buy $16 → $32
Sep-01-20Initiated BTIG Research Buy $23
Jul-15-20Reiterated H.C. Wainwright Buy $7 → $20
Feb-25-21 09:00AM  
Jan-25-21 01:50AM  
Jan-21-21 03:53PM  
Jan-13-21 08:00AM  
Nov-27-20 10:59AM  
Nov-17-20 10:33AM  
Nov-09-20 07:00AM  
Nov-05-20 04:00PM  
Oct-29-20 08:30AM  
Oct-26-20 07:51AM  
Oct-05-20 09:00AM  
Sep-23-20 06:00AM  
Sep-16-20 07:00AM  
Sep-14-20 07:00AM  
Sep-03-20 09:00AM  
Sep-01-20 09:00AM  
Aug-13-20 09:00AM  
Aug-05-20 04:01PM  
Aug-03-20 07:00AM  
Jul-31-20 07:00AM  
Jul-27-20 07:00AM  
Jul-20-20 04:57PM  
Jul-16-20 09:15AM  
Jul-15-20 04:10PM  
Jul-14-20 04:16PM  
Jul-13-20 04:16PM  
Jul-09-20 09:00AM  
Jun-24-20 05:21AM  
Jun-11-20 09:00AM  
May-19-20 09:00AM  
May-14-20 09:00AM  
May-11-20 09:00AM  
May-06-20 04:20PM  
Apr-28-20 09:00AM  
Apr-23-20 09:00AM  
Apr-22-20 10:55AM  
Apr-20-20 09:00AM  
Mar-16-20 05:35AM  
Mar-11-20 09:00AM  
Mar-05-20 09:00AM  
Feb-27-20 09:00AM  
Feb-10-20 09:08AM  
Jan-29-20 08:25AM  
Jan-02-20 09:00AM  
Dec-17-19 09:00AM  
Dec-02-19 09:00AM  
Nov-26-19 06:00AM  
Nov-25-19 08:05AM  
Nov-19-19 09:00AM  
Nov-08-19 04:00PM  
Oct-21-19 03:00PM  
Oct-17-19 09:00AM  
Oct-08-19 09:00AM  
Sep-24-19 10:20AM  
Sep-23-19 09:03AM  
Sep-20-19 10:02AM  
Sep-17-19 09:05AM  
Sep-12-19 08:30AM  
Sep-05-19 08:33AM  
Sep-04-19 09:06AM  
Aug-21-19 02:25PM  
Aug-13-19 07:25AM  
Aug-12-19 09:01AM  
Aug-08-19 08:30AM  
Aug-06-19 03:40PM  
Aug-05-19 09:01AM  
Aug-01-19 09:01AM  
Jul-25-19 09:01AM  
Jul-03-19 09:01AM  
Jun-27-19 09:03AM  
Jun-11-19 08:30AM  
Jun-10-19 01:35PM  
Jun-04-19 04:45PM  
May-28-19 09:03AM  
May-22-19 10:00AM  
May-16-19 09:04AM  
May-15-19 09:03AM  
May-07-19 11:28AM  
Apr-17-19 09:00AM  
Apr-15-19 11:15AM  
Apr-09-19 01:28PM  
Apr-08-19 09:00AM  
Apr-02-19 09:00AM  
Mar-19-19 09:00AM  
Feb-26-19 09:30AM  
Feb-11-19 08:00AM  
Feb-06-19 09:36PM  
Feb-04-19 08:55AM  
INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on reprogramming the patient's innate immune system to treat cancer Alzheimer's disease, and non-alcoholic steatohepatitis. The company intends to develop and commercialize product candidates to treat hematologic malignancies and solid tumors. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high risk myelodysplastic syndrome; INB03 that treats patients with advanced cancers with elevated biomarkers of inflammation in their blood; XPro1595 for the treatment of Alzheimer's disease; and LivNate to treat patients with non-alcoholic steatohepatitis. The company has license agreements with Xencor, Inc.; Immune Ventures, LLC; University of Pittsburg; and University College London. INmune Bio, Inc. was founded in 2015 and is headquartered in La Jolla, California.